Retraction: Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation (Neuropsychiatr Dis Treat., (2011) 7, (31–38), 10.2147/NDT.S16270);Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic caution transporter assay interpretation

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 31-38

  Hinz, Marty ^a   Stein, Alvin ^b   Neff, Robert ^c   Weinberg, Robert ^d   Uncini, Thomas ^e  

^a Neuroresearch clinics inc   (United States)

^b Stein Orthopedic Associates   (United States)

^c Mental Training inc   (United States)

^d MIAMI UNIVERSITY   (United States)

^e Fairview regional Medical Center Mesabi   (United States)

Author keywords

5 hydroxytryptophan; Attention deficit hyperactivity disorder; L dopa; Organic caution transporter assay interpretation; Tyrosine

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMPHETAMINE; ASCORBIC ACID; ATOMOXETINE; CITRATE CALCIUM; CYSTEINE; DOPAMINE; FOLIC ACID; LEVODOPA; LYSINE; METHYLPHENIDATE; MONOAMINE; ORGANIC CATION TRANSPORTER; PLACEBO; PYRIDOXINE; SELENIUM; SEROTONIN; TYROSINE;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PILOT STUDY; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRESCRIPTION; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SEX DIFFERENCE; URINALYSIS;

EID: 79951602270     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S296323     Document Type: Erratum

References (33)

1. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double blind, placebo controlled study. J Am Acad Child Adolesc Psychiatry. 2004;4:896-904.
2. Trachte G, Uncini T, Hinz M. Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population. Neuropsychiatr Dis Treat. 2009;5:227-235.
3. Hinz M, Stein A, Uncini T. The dual-gate lumen model of renal mono-amine transport. Neuropsychiatr Dis Treat. 2010;6:387-392.
4. Hinz M. Depression. In: Kohlstadt I, editor. Food and Nutrients in Disease Management. Boca Raton, FL: CRC Press; 2009.
5. Hinz M, Stein A, Uncini T. A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole. Neuropsychiatr Dis Treat. 2010;6:741-747.
6. Hinz M, Stein A, Trachte G, Uncini T. Neurotransmitter testing of the urine: A comprehensive analysis. Open Access Journal of Urology. 2010;2:177-183.
7. Stein A, Hinz M. Uncini Amino acid responsive Crohn's disease, a case study. Clin Exp Gastroenterol. 2010;3:171-177.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder I V, Fourth Edition. Text Revised. Washington, DC: American Psychiatric Association; 1994.
9. Shire US Inc. FDA approved prescribing information for neutral sulfate salts of dextroamphetamine and amphetamine. Available from: http://pi.shirecontent.com/PI/PDFs/AdderallXR_USA_ENG.PDF. Accessed Oct 14 2010.
10. ®. FDA approved prescribing information for methylphenidate. Available from: http://www.concerta.net/sites/default/fles/pdf/Prescribing_Info-short.pdf. Accessed Oct 14, 2010.
11. Novartis. FDA approved prescribing information for dexmethylphenidate. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/focalin.pdf. Accessed Oct 14 2010.
12. Lilly. FDA approved prescribing information for atomoxetine. Available from: http://pi.lilly.com/us/strattera-pi.pdf. Accessed Oct 14 2010.
13. ADHD & ADD Information Centre. FDA approved prescribing information for lisdexamfetamine dimesylate. Available from: http://www.adhdinfocentre.com/vyvanse/Vyvanse%20Prescribing%20Information.PDF. Accessed Oct 14 2010.
14. National Institute on Drug Abuse. The neurobiology of ecstasy (MDMA). 2010. Available from: http://www.nida.nih.gov/pubs/teaching/Teaching4/Teaching.html. Accessed Sep 2010.
15. Stenfors C, Yu H, Ross S. Pharmacological characterization of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:222-232.
16. De Abajo F, Jick H, Derby L. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol. 2000;50: 43-47.
17. Meier R, Schlienger R, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol. 2001;52:179-184.
18. Dalton S, Johansen C, Mellemkjær L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding. Arch Intern Med. 2003;163:59-64.
19. Trouvin J, Gardier A, Chanut E. Time course of brain serotonin metabolism after cessation of long-term fuoxetine treatment in the rat. Life Sci. 1993;52:187-192.
20. Advokat C. Literature review: Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. J Atten Disord. 2007;11: 8-16.
21. Ricaurte G, Mechan A, Yuan J, et al. Amphetamine treatment similar to that used in the treatment of adult attention-defcit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Exp Ther. 2005;315:91-98.
22. Berggin P. Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action. International Journal of Risk and Safety in Medicine. 1999;12:3-35.
23. Bright Futures. Vanderbilt ADHD Diagnostic Teacher Rating Scale. Available from: http://www.brightfutures.org/mentalhealth/pdf/professionals/bridges/adhd.pdf. Accessed Oct 14 2010.
24. Koepsell H, Schmitt B, Gorboulev V. Organic cation transporters. Physiol Biochem Pharmacol. 2003;150:36-90.
25. Delgado P, Moreno F. Role of norepinephrine in depression. J Clin Psychiatry. 2000;61 Suppl 1:5-12.
26. Greenhill L, Findling R, Swanson J. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-defcit/hyperactivity disorder. Pediatrics. 2002;109:E39.
27. Wilens T, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-defcit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160:82-90.
28. Stein M, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-defcit/hyperactivity disorder. Pediatrics. 2003;112:404-413.
29. Svanborg P, Thernlund G, Gustafsson P, et al. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18: 725-735.
30. Faraone S, Biederman J, Spencer T, et al. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: A drug-placebo response curve analysis. Behav Brain Funct. 2005;1:16.
31. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
32. US Food and Drug Administration. About Science & Research at FDA. 2010. Available from: http://www.fda.gov/ScienceResearch/AboutScienceResearchatFDA/default.htm. Accessed Nov 9 2010.
33. US Food and Drug Administration. Generally recognized as safe. 2010. Available from: http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/default.htm. Accessed Nov 9 2010.